CARsgen Therapeutics Holdings Future Growth

Future criteria checks 2/6

CARsgen Therapeutics Holdings is forecast to grow earnings and revenue by 22.6% and 110% per annum respectively. EPS is expected to grow by 22.8% per annum. Return on equity is forecast to be -97% in 3 years.

Key information

22.6%

Earnings growth rate

22.8%

EPS growth rate

Biotechs earnings growth	39.3%
Revenue growth rate	110.0%
Future return on equity	-97.0%
Analyst coverage	Low
Last updated	28 Aug 2024

Recent future growth updates

Recent updates

CARsgen Therapeutics Holdings (HKG:2171) Is In A Good Position To Deliver On Growth Plans

Jan 23

Companies Like CARsgen Therapeutics Holdings (HKG:2171) Are In A Position To Invest In Growth

Sep 05

Earnings and Revenue Growth Forecasts

SEHK:2171 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	2,724	-320	N/A	N/A	2
12/31/2025	895	-708	N/A	N/A	2
12/31/2024	240	-680	N/A	N/A	2
6/30/2024	6	-695	-579	-569	N/A
3/31/2024	3	-721	-522	-512	N/A
12/31/2023	N/A	-748	-464	-455	N/A
9/30/2023	N/A	-834	-480	-465	N/A
6/30/2023	N/A	-920	-495	-474	N/A
3/31/2023	N/A	-906	-638	-559	N/A
12/31/2022	N/A	-892	-782	-643	N/A
9/30/2022	13	-810	-846	-640	N/A
6/30/2022	26	-727	-910	-637	N/A
3/31/2022	26	-2,736	-800	-575	N/A
12/31/2021	26	-4,744	-691	-512	N/A
9/30/2021	13	-4,831	-540	-431	N/A
6/30/2021	N/A	-4,917	-390	-350	N/A
3/31/2021	N/A	-2,991	-352	-323	N/A
12/31/2020	N/A	-1,064	-314	-295	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2171 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 2171 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 2171 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 2171's revenue (110% per year) is forecast to grow faster than the Hong Kong market (7.4% per year).

High Growth Revenue: 2171's revenue (110% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2171 is forecast to be unprofitable in 3 years.

CARsgen Therapeutics Holdings Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

CARsgen Therapeutics Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Recent updates

CARsgen Therapeutics Holdings Limited Announces Completion of Enrollment of Confirmatory Phase II Clinical Trial of Satricabtagene Autoleucel in China

CARsgen Therapeutics Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Non-Executive Director recently bought HK$903k worth of stock

Carsgen Therapeutics Holdings Limited Provides Updated Research Results on SATRI-CEL in Nature Medicine And At the 2024 Asco Annual Meeting

Non-Executive Director recently bought HK$937k worth of stock

CARsgen Therapeutics Holdings Limited Submits Responses to FDA Observations

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 21, 2024

CARsgen Therapeutics Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

CARsgen Therapeutics Holdings (HKG:2171) Is In A Good Position To Deliver On Growth Plans

Carsgen Therapeutics Holdings Limited Announces Updated Clinical Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen Therapeutics Holdings Limited Announces CT011 Achieve Investigational New Drug (IND) Clearance from the National Medical Products Administration

CARsgen Therapeutics Holdings Limited Announces Updated Research Results on Zevor-cel At 2023 American Society of Hematology Annual Meeting

CARsgen Therapeutics Holdings Limited Receives Investigational New Drug Clearance from the FDA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

CARsgen Therapeutics Holdings Limited Announces Abstract of Zevorcabtagene Autoleucel Accepted for Poster at 2023 Ash Annual Meeting

CARsgen Therapeutics Holdings Limited Car-Gpc3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Two Patients Achieved over 7 Years of Disease-Free Survival

Companies Like CARsgen Therapeutics Holdings (HKG:2171) Are In A Position To Invest In Growth

CARsgen Therapeutics Holdings Limited to Report First Half, 2023 Results on Aug 22, 2023

CARsgen Therapeutics Holdings Limited Appoints Xiangke Zhao as Independent Non-Executive Director and the Chairperson of the Audit Committee

Carsgen Therapeutics Holdings Limited Announces Resignation of Tak Young So as an Independent Non-Executive Director and Chairman of the Audit Committee

CARsgen Therapeutics Holdings Limited Initiates Patient Enrollment for Phase 2 Clinical Trial for CT041

CARsgen Therapeutics Holdings Limited's CLDN18.2 Mab Ab011 Achieves IND Clearance from the NMPA for the First-Line Combination Treatment of Gastric Cancer

CARsgen Therapeutics Holdings Limited Presents Results on Anti-Claudin18.2-mAb AB011 at ASCO GI

CARsgen Therapeutics Holdings Limited Announces Resignation of Chunhai FAN as Independent Non-Executive Director

Insider recently sold HK$14m worth of stock

CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited Appoints Sylvie Peltier as Senior Vice President of Global Regulatory Affairs

CARsgen Therapeutics Holdings Limited Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

Carsgen Therapeutics Holdings Limited Releases First Clinical Batch from the RTP GMP Manufacturing Facility in North Carolina

CARsgen Therapeutics Holdings Limited Announces Case Report of Long Term Complete Response in Hepatocellular Carcinoma to It's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology

CARsgen Therapeutics Holdings Limited to Report First Half, 2022 Results on Aug 23, 2022

CARsgen Therapeutics Holdings Limited Announces Appointment of Dr. Hua JIANG as Executive Director

CARsgen Therapeutics Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

Insider recently sold HK$8.8m worth of stock

Insider recently sold HK$14m worth of stock

Insider recently sold HK$1.9m worth of stock

Insider recently sold HK$10m worth of stock

Carsgen TheCARsgen Therapeutics Holdings Limited Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

CARsgen Therapeutics Holdings Limited Announces Resignation of Zhao Yachao as Non-Executive Director

Insider recently sold HK$3.0m worth of stock

CARsgen Therapeutics Holdings Limited Announces Results of the Investigator-Initiated Trial of CT041 Were Reported in the Nature Medicine

Less than half of directors are independent

CARsgen Therapeutics Holdings Limited, Annual General Meeting, May 25, 2022

Carsgen Therapeutics Holdings Limited Appoints Dr. Raffaele Baffa as Chief Medical Officer

CARsgen Therapeutics Holdings Limited Announces Approval from Center for Drug Evaluation of National Medical Products Administration of China for the Initiation of the CT041 Confirmatory Phase II Clinical Trial

CARsgen Therapeutics Holdings Limited Announces United States Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to CT041

CARsgen Therapeutics Holdings Limited Announces Clinical Trial Application for Ct041 Authorised by Health Canada

CARsgen Therapeutics Holdings Limited has completed an IPO in the amount of HKD 3.107702 billion.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies